Kimberly Westrich, MA

Employers have a unique role in helping to close health equity gaps among employees and their families, explained Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council.

Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council, discusses the importance of clearly defining the role of patient representatives on pharmacy-and-therapeutics and Medicaid committees.

Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council, highlights upcoming discussions on patient engagement, formulary management, and policy changes, including the Inflation Reduction Act.

Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, discusses key agenda highlights that will be presented at the 2024 AMCP Nexus conference.

Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.

Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, anticipates the 2024 AMCP Annual Conference as an opportunity to engage with fellow managed care pharmacy stakeholders in addressing evolving health policy challenges.

Survey results demonstrate an opportunity to incorporate good practices for high-deductible health plans that can help enrollees maximize value and better navigate their benefits and treatment options.

The authors examined the latest trends in development, implementation, and evaluation of care pathways and the impact of the movement toward value-based care.

We surveyed biopharmaceutical manufacturers and payers to understand the prevalence and characteristics of value-based payment arrangements, as well as their implementation obstacles and success factors.

This study found that brand price at launch and generic entry overstates long-run average pharmaceutical costs, with and without accounting for medical cost offsets.

Care pathways influence quality of care and outcomes. Despite positive trends in development and implementation, further efforts in process transparency and evaluation are required.

Gaps in accountable care measure sets can be addressed efficiently using priority measure types and innovative approaches to measurement.

Assessment of current trends, success factors, and challenges in the use of risk-sharing agreements in the US private sector.

A framework for the role of pharmaceuticals in value-based healthcare, practical examples from organizations that have made the transition, and implementation considerations.